Somatostatin Receptor Biology in Neuroendocrine and Pituitary Tumours: Part 1-Molecular Pathways

Basit Öğe Kaydı
dc.contributor.authorÇakır, Mehtap
dc.contributor.authorDworakowska, Dorota
dc.contributor.authorGrossman, Ashley
dc.date.accessioned2020-03-26T18:05:01Z
dc.date.available2020-03-26T18:05:01Z
dc.date.issued2010
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractNeuroendocrine tumours (NETs) may occur at many sites in the body although the majority occur within the gastroenteropancreatic axis. Non-Gastroenteropancreatic NETs encompass phaeochromocytomas and paragangliomas, medullary thyroid carcinoma, anterior pituitary tumour, broncho-pulmonary NETs and parathyroid tumours. Like most endocrine tumours, NETs also express somatostatin (SST) receptors (subtypes 1-5) whose ligand SST is known to inhibit endocrine and exocrine secretions and have anti-tumour effects. In the light of this knowledge, the idea of using SST analogues in the treatment of NETs has become increasingly popular and new studies have centred upon the development of new SST analogues. We attempt to review SST receptor (SSTR) biology primarily in neuroendocrine tissues, focusing on pituitary tumours. A full data search was performed through PubMed over the years 2000-2009 with keywords 'somatostatin, molecular biology, somatostatin receptors, somatostatin signalling, NET, pituitary' and all relevant publications have been included, together with selected publications prior to that date. SSTR signalling in non-neuroendocrine solid tumours is beyond the scope of this review. SST is a potent anti-proliferative and anti-secretory agent for some NETs. The successful therapeutic use of SST analogues in the treatment of these tumours depends on a thorough understanding of the diverse effects of SSTR subtypes in different tissues and cell types. Further studies will focus on critical points of SSTR biology such as homo- and heterodimerization of SSTRs and the differences between post-receptor signalling pathways of SSTR subtypes.en_US
dc.description.sponsorshipNovartisNovartis; Ipsenen_US
dc.description.sponsorshipA.G. has received Advisory Board and lecture fees from Novartis and Ipsen.en_US
dc.identifier.citationÇakır, M., Dworakowska, D., Grossman, A., (2010). Somatostatin Receptor Biology in Neuroendocrine and Pituitary Tumours: Part 1-Molecular Pathways. Journal of Cellular and Molecular Medicine, 14(11), 2570-2584. DOI:10.1111/j.1582-4934.2010.01125.x
dc.identifier.doi10.1111/j.1582-4934.2010.01125.xen_US
dc.identifier.endpage2584en_US
dc.identifier.issn1582-1838en_US
dc.identifier.issn1582-4934en_US
dc.identifier.issue11en_US
dc.identifier.pmid20629989en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2570en_US
dc.identifier.urihttps://dx.doi.org/10.1111/j.1582-4934.2010.01125.x
dc.identifier.urihttps://hdl.handle.net/20.500.12395/25269
dc.identifier.volume14en_US
dc.identifier.wosWOS:000284773600004en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÇakır, Mehtap
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofJournal of Cellular and Molecular Medicineen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectSomatostatinen_US
dc.subjectSomatostatin Receptoren_US
dc.subjectMolecular Biologyen_US
dc.subjectReceptor Signallingen_US
dc.titleSomatostatin Receptor Biology in Neuroendocrine and Pituitary Tumours: Part 1-Molecular Pathwaysen_US
dc.typeReviewen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5269.pdf
Boyut:
800.87 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
İç Hastalıkları/Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu